ישראל - עברית - Ministry of Health

gsk consumer healthcare, israel ltd - calcium carbonate - טבליות לעיסות - calcium carbonate 750 mg - calcium carbonate - calcium carbonate - treatment of heartburn, calcium supplement.

ישראל - עברית - Ministry of Health

gsk consumer healthcare, israel ltd - lidocaine; tribenoside - פתילות - tribenoside 400 mg; lidocaine 40 mg - tribenoside - tribenoside - local relief of haemorrhoids.

ישראל - עברית - Ministry of Health

gsk consumer healthcare, israel ltd - lidocaine hydrochloride; tribenoside - קרם - tribenoside 5 %; lidocaine hydrochloride 2.12 % - tribenoside - tribenoside - external & internal haemorrhoids

ישראל - עברית - Ministry of Health

מדיק ויז'ן אימגינג סולושונס בע"מ - מומחה

ישראל - עברית - Ministry of Health

"טבע מדיקל (שיווק) בע""מ" - אחות

ישראל - עברית - Ministry of Health

ביומטריקס - רופא - administration of drugs and fluids, and blood sampling through an implanted vascular port

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

ישראל - עברית - Ministry of Health

j-c health care ltd - guselkumab - תמיסה להזרקה - guselkumab 100 mg / 1 ml - guselkumab

ישראל - עברית - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - טבעת וגינלית - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.